NetApp Introduces Continuous Delivery Solution Spot Ocean CD
22.6.2023 15:00:00 EEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today introduced Spot Ocean CD, a continuous delivery solution for Kubernetes. Ocean CD complements and extends Spot Ocean, optimizing delivery of cloud applications by automating deployment strategies across clusters and workloads. The combination of Spot Ocean and Ocean CD extends our Kubernetes automation and optimization solutions to application delivery, reducing complexity and burdens for DevOps teams while connecting how applications are delivered with how they are operated in production to provide greater agility, reliability and efficiency.
Organizations rely on the ability to deploy and operate cloud-native applications with speed, scale and confidence to support critical business priorities and initiatives. However, the already overstretched DevOps teams that they depend on to make that possible face daunting challenges and time-consuming work to deliver increasingly complex applications in a consistent, repeatable and reliable way. The delivery process typically contains hundreds of deployments over multiple clusters and is conducted by dozens of developer stakeholders. These challenges increase the risk of frequent failures in delivery that slow down application innovation and impact reliability, frustrating application teams and adding to DevOps and operations burdens.
Ocean CD automates and optimizes the delivery process, providing uniquely valuable Kubernetes deployment control without compromising reliability, security or efficiency. With Ocean CD, DevOps teams can set and maintain deployment strategies across multiple clusters and workloads, while giving developers the ability to identify and prevent potential incidents in early stages that could result in inefficiency and costly failures. Ocean CD enables teams to transform from a basic software release process into a gradual deployment process using proven deployment strategies. Additionally, Ocean CD limits potential failures due to software changes by utilizing gradual releases, continuous real-time verification, automatic rollback and granular visibility for service owners. Using Ocean CD together with Spot Ocean and the rest of the Spot by NetApp portfolio of solutions enables organizations to optimize and scale the way they deploy and operate cloud-native applications, simplifying and improving their application delivery and operations pipeline.
“Organizations rely on being able to quickly and reliably deliver and evolve cloud applications to support their business priorities, but too often find themselves hindered by complexity and inefficiency,” said Haiyan Song, Executive Vice President and General Manager, CloudOps at NetApp. “Spot Ocean CD extends our automation and optimization to application delivery, enabling DevOps teams to simplify, standardize and automate the complex Kubernetes software delivery process across any cloud and Kubernetes cluster so that teams can innovate and operate applications rapidly, reliably and efficiently.”
Ocean CD provides DevOps teams with the following key capabilities:
- Visibility into code rollout in a clear visual interface to easily manage multiple services across clusters in one place, which simplifies complex Kubernetes software delivery processes with automation and gradual software deployment, centralizing all deployment-related activities and views in one spot. It also allows a generic model that makes it easy to dynamically manage or change multiple deployment pipelines for all services across all clusters and cloud providers.
- Better control to deploy software changes and rollouts into production with confidence based on clear metrics and policies that identify and fix hidden failure points of deployments without slowing down releases. Ocean CD detects and intercepts deployments, adding intelligent CD capabilities such as Canary or Blue-Green rollout strategies, traffic management, verification-driven process and managed failure policies for smarter rollbacks with better control, allowing users to gain the full power and agility out of Kubernetes with peace of mind and minimal overhead.
- An enterprise-ready continuous delivery product with the right automation to eliminate bottlenecks and manual overhead, simplifying the release of application changes, and ability to scale over hundreds of clusters and services. Ocean CD offers enterprise-grade support and features including SSO, granular permissions management for developers, notifications, multi-cluster management, manager dashboards and frequent updates aligned to customer feedback.
"With Ocean CD, we can remove bottlenecks in a way that allows us to be the best we can be in our CD environment,” said Matthieu Antoine, Senior Staff System Engineer at JUMO. “Ocean CD creates a seamless process that’s as automated as it can be, so developers can spend as little time around it as possible. It also reduces production errors and provides better orchestration of complex processes that require a lot of time, such as migrating Kubernetes clusters to newer versions. With this automation now in place, we can better deliver on our greater mission, which is offering reliable financial services to people that so far had no access to such services at all.”
Spot Ocean CD is now available via the Spot console UI, API or CLI. To learn more visit https://spot.io/product/ocean-cd/.
Additional Resources
Announcing Ocean CD Availability
Continuous Verification Key Concepts: Ocean CD Metric and Custom Verifications
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services, and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230622769157/en/
Contact information
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Kris Newton
NetApp
kris.newton@netapp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
